MetroGel is a U.S. brand name for prescription metronidazole gel 1%, formulated for application to the skin in rosacea care. Understanding this exact product matters because metronidazole also appears as vaginal gels, oral tablets and different dermatologic strengths. A brand match requires more than an ingredient name: the route, vehicle, concentration and particular labeled preparation must be correct. The topical metronidazole overview places this product within the broader rosacea formulation family.
MetroGel is particularly easy to confuse with the historical MetroGel-Vaginal name and with topical gels of 0.75%, so route and concentration must appear together. The principal pharmacy task is to distinguish the historical or current branded gel listing from approved generic formulations and from similarly named products. Brand MetroGel 1% is a dermal product with labeled use for rosacea; product records do not guarantee a brand carton remains in a given pharmacy. A label or FDA record establishes product identity, not a live store offer. If a prescription names MetroGel, a pharmacist can determine whether that exact product can be obtained or whether the prescriber should consider an appropriately authorized alternative.
This page is a brand-specific reference rather than a second buying hub or an advertisement. It explains the branded gel's labeling, its vehicle, 1% strength and regulatory supply context. For the form-specific guide see the metronidazole gel product details; for general access questions see the gel pharmacy access guide. Do not change medication, concentration or application frequency based on a catalogue filter.
MetroGel contains metronidazole at 1% in a gel vehicle intended for external skin use. Its labeled context is inflammatory papules and pustules of rosacea; it is not an oral antimicrobial prescription or an intravaginal BV product. Because the drug name crosses very different indications and sites of administration, the pharmacy record must explicitly identify the gel formulation and the skin route. A product whose package does not make those details clear needs clarification.
MetroGel 1% is a gel for inflammatory rosacea lesions, and its directions are not interchangeable with the five-day vaginal-gel regimen described in BV guidance. A pharmacist can compare the manufacturer's label, prescribing order and available package identification. A patient should not use a vaginal applicator product on the face or infer that an oral dose is equivalent to a topical amount. The dermatologic product belongs to a distinct treatment plan selected by a healthcare professional.
| Product or listing | Relevant identity | Why it is not interchangeable |
|---|---|---|
| MetroGel | 1% topical gel | Exact brand-specific label and route must match |
| Topical metronidazole generic | Formulation and 1% must be verified | Generic approval applies to particular strengths and forms |
| Other skin metronidazole forms | 0.75% skin gel and 0.75% cream or lotion | Cream, gel and lotion have different vehicles and labeling |
| Metronidazole vaginal gel | Intravaginal product for BV | Wrong route even when a similar percentage appears |
The official DailyMed labeling for MetroGel supplies the product name, formulation, ingredients, labeled clinical use, precautions and—where recorded—package identifiers. The label should be the starting point for interpreting any advertised branded medicine. An older document may remain accessible even when a specific marketed package has changed or ended. That is not a contradiction: labeling is a regulatory record, while inventory exists at an individual pharmacy and supplier.
The word MetroGel has appeared in more than one route-specific historical context; readers should verify whether a label is explicitly the dermal 1% formulation, not MetroGel-Vaginal. To assess the current U.S. regulatory context, combine the exact label with FDA approval or marketing information and ask a pharmacist to verify the present-day product being dispensed. Avoid statements such as 'always available' or 'brand guaranteed' merely because a drug database still recognizes the name.
The gel base is more than a texture preference. Its formulation contains inactive ingredients that affect the way a product spreads, dries, feels on the skin and is packaged. Those properties may influence individual tolerability, but they do not establish that one formulation is universally more effective than another. A person experiencing stinging, dryness or another concern should discuss the actual product with the prescriber instead of switching vehicles independently.
Gel vehicles can differ in nonactive components from creams and lotions, even where the same drug is present. A person concerned about skin feel or irritation should review ingredients on the exact metronidazole gel rather than assume all gels have identical composition. The treatment plan can also include nonprescription gentle skincare and sun protection as advised for rosacea; neither these measures nor metronidazole itself should be represented as a cure for every form of facial redness. The cream-versus-gel comparison and other formulation guides address these decisions in greater detail.
The label strength is the concentration of metronidazole in the formulation, not a patient-selected dose or a universal equivalence rule. A 1% gel cannot be substituted for a product with another concentration or vehicle merely by applying more or less. The prescription should identify the intended product, application instructions and amount to dispense. Where an order is ambiguous, the pharmacist may need to contact the prescriber rather than guessing.
MetroGel 1% delivers a 1% topical formulation; a 0.75% gel has its own label and directions. A concentration change is a medication change requiring professional review rather than a patient calculation. In particular, metronidazole vaginal gels can also be labeled with percentages, but they have a different route, applicator system and indication. The vaginal versus topical gel comparison is useful when packaging names could be confused.
FDA-approved 1% metronidazole topical gel generic products exist, but generic status is product-specific and should be checked by labeler and exact formulation. The FDA Orange Book provides information on approved products and therapeutic-equivalence evaluations, but such information must be checked at the actual form and strength level. A pharmacy's generic offer may come from a different labeler or package than the brand. A shared active ingredient by itself is not proof of approved substitution across forms or concentrations.
Brand MetroGel 1% is a dermal product with labeled use for rosacea; product records do not guarantee a brand carton remains in a given pharmacy. The 1% dermal gel is not an interchangeable 1% version of Noritate cream. If the prescribed brand cannot be obtained, ask the pharmacist to check whether the order permits an appropriate approved alternative. Any departure from the intended formulation should be reviewed with the prescriber where required. This brand page does not invent a list of distributors, claim available stock or equate all metronidazole products.
A particularly costly product-identification error arises when a search for MetroGel also shows historical material labeled MetroGel-Vaginal. The ordinary MetroGel brand page here describes a 1% gel for external facial skin use in rosacea. A vaginal metronidazole gel may contain 0.75% drug, be supplied with applicators and be labeled for bacterial vaginosis. The shared first part of the brand word is not an authorization to exchange the products.
A correct dispensing record should state the product's route and concentration, not just 'metronidazole gel.' Even when a website filters results to 1%, verify that the order is for a topical dermatologic preparation. If the pharmacy asks whether an older MetroGel listing is the intended item, compare the exact label with the prescriber rather than resolving the question from a picture alone.
Generic 1% topical metronidazole gel appears in U.S. labeling from specific manufacturers, including ANDA-labeled products. A generic tube may have different inactive ingredients, packaging or supplier than the branded MetroGel presentation. FDA-approved generic status rests on a specific application and equivalence assessment, not on a retailer grouping every 1% product into one category.
This matters especially when comparing generic 1% gel with generic 0.75% skin gel: both are topical, but their concentrations and labels are different. For a prescription naming MetroGel, a licensed pharmacist can explain any permissible manufacturer substitution while preserving the intended route and regimen. A lower generic price does not authorize changing product strength.
Topical metronidazole products such as MetroGel are discussed in care for inflammatory rosacea lesions, including papules and pustules. Rosacea can also involve flushing, persistent redness, sensitive skin or other findings that may respond differently to various treatments. The clinician determines the diagnosis and whether this gel is suitable, rather than treating any facial redness as an indication for an antibiotic.
MetroGel 1% has its own clinical-trial evidence and FDA labeling for inflammatory rosacea lesions, not for every cause of facial redness. Its 1% dermal gel is described with once-daily application in the product label, unlike the schedules printed for some older 0.75% cream and lotion labels. Those differences should prompt a prescriber-specific discussion, not an attempt to compare products by concentration or frequency alone. The 0.75% versus 1% gel comparison focuses on that narrower formulation question.
A MetroGel order should identify 1% metronidazole gel for skin use, with the quantity and directions selected by the prescriber. The dispensing pharmacist can verify an eligible generic 1% topical gel against the relevant FDA records; an offered 0.75% gel, 1% cream or similarly named vaginal product is not the same item. For an online transaction, also verify that a licensed U.S. pharmacy requires the prescription and can provide direct pharmacist counseling before dispensing.
The exact pump or tube presentation matters for a price quote, and an online search may mix old and new package images. Ask the pharmacy which NDC and manufacturer are actually being used. For details of broader prescribing mechanics, see topical metronidazole prescription access. If a brand cannot be ordered, a pharmacist may propose an appropriately approved option rather than declaring that any metronidazole cream, lotion or gel is equivalent.
MetroGel is intended for skin use in the prescribed areas. The product's own label addresses issues such as hypersensitivity, local irritation and avoiding eye contact. Topical systemic exposure is not identical to oral administration, but this is not a reason to ignore the prescribing information or other medicine use. People with reactions or changing symptoms should contact their clinician rather than repeatedly experimenting with different formulations.
If MetroGel causes troublesome burning, dryness or persistent irritation, seek advice rather than applying extra gel or changing to a different formulation on your own. Its prescribing information requires avoidance of the eyes and use only for the diagnosed condition. Follow-up should assess whether papules and pustules have responded; persistent vascular redness may call for a separate clinical evaluation rather than assuming that stronger metronidazole is needed.
Brand MetroGel listings and 1% generic gel quotes can differ; a generic price should not be compared with a branded bottle or tube of another size. A quote for a different concentration, package size or rosacea vehicle is not a valid like-for-like price comparison. Insurance formularies, deductibles, preferred pharmacies and branded versus generic dispensing may affect out-of-pocket costs even when the prescribed active ingredient has not changed.
For a focused brand-versus-generic discussion, see MetroGel 1% cost and coverage. Ask separately for the exact prescribed 1% dermal gel, its pack size and the allowable generic alternative; a lower quote for 0.75% gel or a vaginal product cannot answer the same question. Coverage and stock should be confirmed at the dispensing pharmacy rather than inferred from a label archive.
Before paying or beginning treatment, verify that the label identifies a topical skin gel, metronidazole 1%, the correct brand or pharmacist-approved generic, prescribed directions and package. Check whether the drug is actually intended for rosacea rather than BV or another infection, and read any storage or handling instructions supplied with the medicine.
If any item is inconsistent—especially an unfamiliar route, alternate concentration or discontinued branded package—ask the dispensing pharmacist for clarification and prescriber coordination. Do not accept a catalog item identified as vaginal gel despite a familiar MetroGel search phrase. The aim is a correct and verified medicine, not the fastest possible checkout.
MetroGel is a branded prescription metronidazole gel 1% for external skin use in rosacea care.
No. MetroGel is a dermatologic skin product; bacterial vaginosis vaginal products have different formulations and routes.
No. The U.S. MetroGel product is prescription-only.
Yes, approved generic 1% topical metronidazole gels exist; check the specific equivalent and current pharmacy listing.
Not without appropriate pharmacist review and any required prescriber authorization. Exact route, concentration and formulation must be considered.
The product is for topical skin use; label precautions require avoiding the eyes. Follow the prescriber’s directions for appropriate application sites.
No. Oral Flagyl and dermatologic MetroGel have different routes, exposure patterns and clinical purposes.
Brand supply and packages vary by pharmacy and date. A product label or historical brand record is not real-time inventory.
Product identity, branded versus generic dispensing, package quantity, insurance terms and pharmacy selection may affect cost.
Confirm topical route, 1% concentration, gel dosage form, prescription directions, active ingredient and licensed pharmacy dispensing.